|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF771 |
Gene summary for ZNF771 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF771 | Gene ID | 51333 |
| Gene name | zinc finger protein 771 | |
| Gene Alias | DSC43 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B2R9V3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51333 | ZNF771 | LZE22D1 | Human | Esophagus | HGIN | 5.14e-03 | 1.70e-01 | 0.0595 |
| 51333 | ZNF771 | LZE22T | Human | Esophagus | ESCC | 1.54e-04 | 2.69e-01 | 0.068 |
| 51333 | ZNF771 | LZE24T | Human | Esophagus | ESCC | 4.28e-25 | 6.53e-01 | 0.0596 |
| 51333 | ZNF771 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 1.71e-01 | 0.0655 |
| 51333 | ZNF771 | P1T-E | Human | Esophagus | ESCC | 7.43e-09 | 3.70e-01 | 0.0875 |
| 51333 | ZNF771 | P2T-E | Human | Esophagus | ESCC | 6.03e-56 | 8.99e-01 | 0.1177 |
| 51333 | ZNF771 | P4T-E | Human | Esophagus | ESCC | 3.74e-25 | 5.17e-01 | 0.1323 |
| 51333 | ZNF771 | P5T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.79e-01 | 0.1327 |
| 51333 | ZNF771 | P8T-E | Human | Esophagus | ESCC | 1.08e-15 | 3.04e-01 | 0.0889 |
| 51333 | ZNF771 | P9T-E | Human | Esophagus | ESCC | 1.65e-09 | 2.23e-01 | 0.1131 |
| 51333 | ZNF771 | P10T-E | Human | Esophagus | ESCC | 1.77e-22 | 3.70e-01 | 0.116 |
| 51333 | ZNF771 | P11T-E | Human | Esophagus | ESCC | 6.27e-12 | 4.54e-01 | 0.1426 |
| 51333 | ZNF771 | P12T-E | Human | Esophagus | ESCC | 1.29e-40 | 7.58e-01 | 0.1122 |
| 51333 | ZNF771 | P15T-E | Human | Esophagus | ESCC | 2.04e-18 | 3.14e-01 | 0.1149 |
| 51333 | ZNF771 | P16T-E | Human | Esophagus | ESCC | 1.16e-26 | 4.76e-01 | 0.1153 |
| 51333 | ZNF771 | P17T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.79e-01 | 0.1278 |
| 51333 | ZNF771 | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 2.71e-01 | 0.1662 |
| 51333 | ZNF771 | P20T-E | Human | Esophagus | ESCC | 2.73e-21 | 3.79e-01 | 0.1124 |
| 51333 | ZNF771 | P21T-E | Human | Esophagus | ESCC | 3.19e-23 | 4.22e-01 | 0.1617 |
| 51333 | ZNF771 | P22T-E | Human | Esophagus | ESCC | 1.15e-45 | 7.15e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF771 | SNV | Missense_Mutation | novel | c.127A>G | p.Met43Val | p.M43V | Q7L3S4 | protein_coding | tolerated(1) | benign(0) | TCGA-CN-4728-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | vectibix | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |